Increasing HCV treatment in primary care is crucial to achieving HCV elimination in Australia by 2030. This course aims to empower general practitioners, nurse practitioners and other prescribing practitioners with the skills and confidence to diagnose, assess, manage, and treat HCV in primary care.
Training delivery utilises a blended learning approach with expert-led presentations and facilitated case discussions delivered by specialists, General Practitioners, Nurse Practitioners and Peer/Lived Experience workforce with expertise in HCV management and treatment.
Date, Time, Platform:
- Date: Wednesday, 25 March 2026
- Times:
- NSW, VIC, ACT, TAS: 7:30pm – 9:30pm (AEDT)
- SA: 7:00pm – 9:00pm (ACDT)
- QLD: 6:30pm – 8:30pm (AEST)
- NT: 6:00pm – 8:00pm (ACST)
- WA: 4:30pm – 6:30pm (AWST)
- Platform: Online – Zoom
Presenters:
Presenters TBC…
Learning Outcomes:
- Identify when screening and testing for HCV is indicated
- Interpret HCV test results
- Discuss required pre-treatment assessments
- Determine which treatment, monitoring, and follow-up is required.
Recommended Resources:
- Clinical Extensions of Hepatitis C (Optional Pre-Course Activity)
- Click here to access this learning module.
- GPs completing the optional pre-course activity will be awarded the approved 1 Educational Activity hours in the 2023-2025 RACGP Triennium.
CPD & Endorsement:
- RACGP:
This course has been approved as a CPD activity by RACGP for the 2023-2025 triennium. Educational Activities: 1.5 Educational Activity hours. Reviewing Performance: 1.0 Reviewing Performance hours.
RACGP Activity Number: 891606
- ACCRM:
This course has been approved by ACRRM as an accredited activity. Allocated total XX PDP units: 1.5 Educational Activity hours. Reviewing Performance: 1.0 Reviewing Performance hours.
Funding:
This course received funding from the Australian Government Department of Health, Disability and Ageing.
Target Audience:
General Practitioners, Nurse Practitioners, and other practitioners prescribing or intending to prescribe s85 direct-acting antiviral medication for HCV in primary care settings.
